August 2019

Contents

Early access

• Dolutegravir for younger children: results from the ODYSSEY trial

• Dolutegravir-based first-line non-inferior to efavirenz-based ART but associated with substantial weight gain: results from the ADVANCE study

• High efficacy from switching to bictegravir/F/TAF in virally suppressed participants – including analyses by baseline drug resistance

• Four days on, three days off is NOT as effective as daily ART: French study results need to be interpreted with caution

• Cabotegravir/rilpivirine long-acting injectable HIV drugs submitted to EMA

Special reports

• Fit for purpose: antiretroviral treatment optimisation